Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 7876064, 12 pages
https://doi.org/10.1155/2017/7876064
Research Article

Curcumin Suppresses Intestinal Fibrosis by Inhibition of PPARγ-Mediated Epithelial-Mesenchymal Transition

1First Clinical Medical College, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, China
2Department of Colorectal Surgery, The Yancheng Affiliated Hospital of Nanjing University of Chinese Medicine, No. 53 People’s Road, Yancheng 224001, China
3Department of Colorectal Surgery, The Third Affiliated Hospital of Nanjing University of Chinese Medicine, No. 1 Jinling Road, Nanjing 210001, China

Correspondence should be addressed to Li Zeng; moc.361@ilgnibgnez

Received 18 October 2016; Revised 4 December 2016; Accepted 21 December 2016; Published 22 January 2017

Academic Editor: Kuzhuvelil B. Harikumar

Copyright © 2017 Su Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. J. Freeman, “Natural history and clinical behavior of Crohn's disease extending beyond two decades,” Journal of Clinical Gastroenterology, vol. 37, no. 3, pp. 216–219, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Froehlich, P. Juillerat, C. Mottet et al., “Fibrostenotic Crohn's disease,” Digestion, vol. 76, no. 2, pp. 113–115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Speca, I. Giusti, F. Rieder, and G. Latella, “Cellular and molecular mechanisms of intestinal fibrosis,” World Journal of Gastroenterology, vol. 18, no. 28, pp. 3635–3661, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Rieder and C. Fiocchi, “Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science,” Current Opinion in Gastroenterology, vol. 24, no. 4, pp. 462–468, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. M. Lee, S. Dedhar, R. Kalluri, and E. W. Thompson, “The epithelial-mesenchymal transition: new insights in signaling, development, and disease,” The Journal of Cell Biology, vol. 172, no. 7, pp. 973–981, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Li, F. Dai, Q. Peng, and H. Gan, “Progress in study on mechanism of intestinal fibrosis in inflammatory bowel disease,” Chinese Journal of Gastroenterology, vol. 18, no. 8, pp. 503–505, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. J. Xu, S. Lamouille, and R. Derynck, “TGF-β-induced epithelial to mesenchymal transition,” Cell Research, vol. 19, no. 2, pp. 156–172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Miettinen, R. Ebner, A. R. Lopez, and R. Derynck, “TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors,” The Journal of Cell Biology, vol. 127, no. 6, pp. 2021–2036, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. T. A. Wynn, “Cellular and molecular mechanisms of fibrosis,” Journal of Pathology, vol. 214, no. 2, pp. 199–210, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. J. W. O'Connor and E. W. Gomez, “Biomechanics of TGFβ-induced epithelial-mesenchymal transition: implications for fibrosis and cancer,” Clinical and Translational Medicine, vol. 3, article 23, 2014. View at Publisher · View at Google Scholar
  11. G. Latella, A. Vetuschi, R. Sferra et al., “Smad3 loss confers resistance to the development of trinitrobenzene sulfonic acid–induced colorectal fibrosis,” European Journal of Clinical Investigation, vol. 39, no. 2, pp. 145–156, 2009. View at Publisher · View at Google Scholar
  12. A. Di Sabatino, C. L. Jackson, K. M. Pickard et al., “Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures,” Gut, vol. 58, no. 6, pp. 777–789, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. G. Shi and J. Massagué, “Mechanisms of TGF-β signaling from cell membrane to the nucleus,” Cell, vol. 113, no. 6, pp. 685–700, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Latella, R. Sferra, S. Speca, A. Vetuschi, and E. Gaudio, “Can we prevent, reduce or reverse intestinal fibrosis in IBD?” European Review for Medical and Pharmacological Sciences, vol. 17, no. 10, pp. 1283–1304, 2013. View at Google Scholar · View at Scopus
  15. C. Rousseaux and P. Desreumaux, “The peroxisome-proliferator-activated gamma receptor and chronic inflammatory bowel disease (PPARγ and IBD),” Journal de la Société de Biologie, vol. 200, no. 2, pp. 121–131, 2006. View at Google Scholar
  16. C. Zhao, W. Chen, L. Yang, L. Chen, S. A. Stimpson, and A. M. Diehl, “PPARγ agonists prevent TGFβ1/Smad3-signaling in human hepatic stellate cells,” Biochemical and Biophysical Research Communications, vol. 350, no. 2, pp. 385–391, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. K. L. Houseknecht, B. M. Cole, and P. J. Steele, “Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: a review,” Domestic Animal Endocrinology, vol. 22, no. 1, pp. 1–23, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Zhang, T. Cheng, M. Zheng et al., “Activation of peroxisome proliferator-activated receptor-γ inhibits transforming growth factor-β1 induction of connective tissue growth factor and extracellular matrix in hypertrophic scar fibroblasts in vitro,” Archives of Dermatological Research, vol. 301, no. 7, pp. 515–522, 2009. View at Publisher · View at Google Scholar
  19. L. Yang, S. A. Stimpson, L. Chen, W. W. Harrington, and D. C. Rockey, “Effectiveness of the PPARγ agonist, GW570, in liver fibrosis,” Inflammation Research, vol. 59, no. 12, pp. 1061–1071, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Kawai, T. Masaki, S. Doi et al., “PPAR-γ agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-β,” Laboratory Investigation, vol. 89, no. 1, pp. 47–58, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Aoki, T. Maeno, K. Aoyagi et al., “Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis,” Respiration, vol. 77, no. 3, pp. 311–319, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Talukdar and R. K. Tandon, “Pancreatic stellate cells: new target in the treatment of chronic pancreatitis,” Journal of Gastroenterology and Hepatology, vol. 23, no. 1, pp. 34–41, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Chen, Y.-W. He, W.-Q. Liu, and J.-H. Zhang, “Rosiglitazone prevents murine hepatic fibrosis induced by Schistosoma japonicum,” World Journal of Gastroenterology, vol. 14, no. 18, pp. 2905–2911, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. B. B. Aggarwal, A. Kumar, and A. C. Bharti, “Anticancer potential of curcumin: preclinical and clinical studies,” Anticancer Research, vol. 23, no. 1, pp. 363–398, 2003. View at Google Scholar · View at Scopus
  25. B. B. Aggarwal and K. B. Harikumar, “Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases,” International Journal of Biochemistry and Cell Biology, vol. 41, no. 1, pp. 40–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. Sharma, A. J. Gescher, and W. P. Steward, “Curcumin: the story so far,” European Journal of Cancer, vol. 41, no. 13, pp. 1955–1968, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Q.-Y. Yao, B.-L. Xu, J.-Y. Wang, H.-C. Liu, S.-C. Zhang, and C.-T. Tu, “Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats,” BMC Complementary and Alternative Medicine, vol. 12, article 156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Punithavathi, N. Venkatesan, and M. Babu, “Curcumin inhibition of bleomycin-induced pulmonary fibrosis in rats,” British Journal of Pharmacology, vol. 131, no. 2, pp. 169–172, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Lipecka, C. Norez, N. Bensalem et al., “Rescue of ΔF508-CFTR (cystic fibrosis transmembrane conductance regulator) by curcumin: involvement of the keratin 18 network,” The Journal of Pharmacology and Experimental Therapeutics, vol. 317, no. 2, pp. 500–505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. Y.-M. Nan, F. Han, L.-B. Kong et al., “Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice,” Scandinavian Journal of Gastroenterology, vol. 46, no. 3, pp. 358–369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. H.-M. Wang, Y.-X. Zhao, S. Zhang et al., “PPARγ agonist curcumin reduces the amyloid-β-stimulated inflammatory responses in primary astrocytes,” Journal of Alzheimer's Disease, vol. 20, no. 4, pp. 1189–1199, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. S. N. Flier, H. Tanjore, E. G. Kokkotou, H. Sugimoto, M. Zeisberg, and R. Kalluri, “Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis,” Journal of Biological Chemistry, vol. 285, no. 26, pp. 20202–20212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. M. Y. Zhu, Y. M. Lu, Y. X. Ou, H. Z. Zhang, and W. X. Chen, “Dynamic progress of 2,4,6-trinitrobenzene sulfonic acid induced chronic colitis and fibrosis in rat model,” Journal of Digestive Diseases, vol. 13, no. 8, pp. 421–429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  34. L. A. Dieleman, A. S. Pena, S. G. M. Meuwissen, and E. P. Van Rees, “Role of animal models for the pathogenesis and treatment of inflammatory bowel disease,” Scandinavian Journal of Gastroenterology, Supplement, vol. 32, no. 223, pp. 99–104, 1997. View at Google Scholar · View at Scopus
  35. S. Videla, J. Vilaseca, C. Medina et al., “Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis,” Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 2, pp. 940–945, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. C. Fiocchi and P. Kay Lund, “Themes in fibrosis and gastrointestinal inflammation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 300, no. 5, pp. G677–G683, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. R. A. Taylor and M. C. Leonard, “Curcumin for inflammatory bowel disease: a review of human studies,” Alternative Medicine Review, vol. 16, no. 2, pp. 152–156, 2011. View at Google Scholar · View at Scopus
  38. B. C. Willis and Z. Borok, “TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 293, no. 3, pp. L525–L534, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Chen and J. Xu, “Activation of PPARγ by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR,” American Journal of Physiology - Gastrointestinal and Liver Physiology, vol. 288, no. 3, pp. G447–G456, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. R. Li, Y. Wang, Y. Liu et al., “Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not smad pathway in renal tubular epithelial cells,” PLoS ONE, vol. 8, no. 3, Article ID e58848, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. M. K. Phanish, N. A. Wahab, P. Colville-Nash, B. M. Hendry, and M. E. C. Dockrell, “The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFβ1 responses in human proximal-tubule epithelial cells,” Biochemical Journal, vol. 393, no. 2, pp. 601–607, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Li, Y. Wang, Y. Liu et al., “Curcumin inhibits transforming growth factor-β1-induced EMT via PPARγ pathway, not Smad pathway in renal tubular epithelial cells,” PLoS ONE, vol. 8, no. 3, Article ID e58848, 2013. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Kapoor, M. McCann, S. Liu et al., “Loss of peroxisome proliferator-activated receptor γ in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis,” Arthritis and Rheumatism, vol. 60, no. 9, pp. 2822–2829, 2009. View at Publisher · View at Google Scholar · View at Scopus